MHRA Interview & New Speaker Announced at Immuno-Oncology 2018

SMi Reports: In the run up to Immuno-Oncology 2018, SMi announces the conference’s newest session led by ImmuneBiotech AB, as well as an exclusive speaker interview with the MHRA.

 

There’s just over 1 week to go until SMi’s Immuno-Oncology conference on 26th – 27th September 2018 in London, UK (http://www.immuno-oncology-conference.com/pharphorpr), set to bring together an unrivalled gathering of industry leaders and scientific pioneers to explore the potential of targeted immuno-therapies.

 

A new session on day one has recently been announced, with Shahram Lavasani, the CEO of ImmuneBiotech AB presenting on “Could the Microbiome Boost Cancer Immunotherapy?”. Shahram will be providing his expertise and experience on the understanding of the dynamics and function of the human microbiome in health and disease, dysbiosis and cancer therapy, and microbial interventions.

 

In the run up to the two-day conference, SMi also caught up with Dr Andrew Exley, a Medical Assessor, for an exclusive interview to discuss his role in the MHRA, the biggest challenges and innovations in Immuno-Oncology, and what he hopes to gain from this year’s meeting.

 

Interview Snapshot:

Q. What would you say is the biggest barrier to implementation of Immuno-Oncological therapies in common treatment plans?

A. The biggest barriers to implementation of Immuno-Oncological therapies into common treatment plans are the identification, validation and interpretation of clinically meaningful biomarkers, surrogate endpoints and clinical trial goals. Overcoming these clinical barriers has a critical role in addressing the economic concerns about Immuno-Oncology therapies.

Q. What do you think has been the greatest innovation within Immuno-Oncology over the last year or two? Where do you see Immuno-Oncology leading us over the next few years?

A. The potential and pitfalls within Immuno-Oncology are exemplified by recent developments in checkpoint blockade and CAR-T cells. Progress in targeting and optimising these therapies is anticipated.

 

Dr Exley is a Medical Assessor in the Biologicals and Biotechnology Unit within the Licensing Division of the MHRA in London. He provides bench to bedside expertise in immunology and regulatory affairs including diagnostics, biomarkers, and clinical endpoints, from a background of extensive experience as a consultant immunologist.

 

Dr Exley will also be speaking and presenting at this year’s conference on “Generating Symbiosis with Regulatory Affairs in Immuno-Oncology”. The full interview is now available to download on the event website’s download section at http://www.immuno-oncology-conference.com/pharphorpr

 

2018 Event Highlights:

 

  • Learn about targeting immune checkpoints with Humabody VH Therapeutics
  • Discover advances in durable disease control with Keytruda as an anti-cancer therapy
  • Discuss the tumour mutation burden and the potential of its use as an indication of treatment choice
  • Develop an understanding of unwanted immunogenicity and functionality testing of immuno-oncology drugs
  • Gain insight into new techniques, such as emerging applications of liquid biopsies

 

Visit the website to find out more, download the latest brochure, full speaker line-up and other exclusive content, and register your place: http://www.immuno-oncology-conference.com/pharphorpr

 

—- END —-

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk